Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2012

01.02.2012 | Original article

Salvage radiotherapy in patients with recurrent esophageal carcinoma

verfasst von: K. Fakhrian, N. Gamisch, T. Schuster, R. Thamm, M. Molls, H. Geinitz

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The feasibility and effectiveness of radiotherapy in the management of recurrent esophageal carcinoma (REC) is reported.

Patients and methods

A consecutive cohort of 54 patients with rcT1-4, rcN0-1, or cM0 recurrent esophageal carcinoma (69% squamous cell carcinoma, 31% adenocarcinoma) was treated between 1988 and 2010. The initial treatment for these patients was definitive radiochemotherapy, surgery alone, or neoadjuvant radiochemotherapy + surgical resection in 8 (15%), 33 (61%), and 13 (24%) patients, respectively. The median time to recurrence from initial treatment was 19 months (range 4–79 months). The site of the recurrence was anastomotic or local, nodal, or both in 63%, 30%, and 7% of patients, respectively. Salvage radio(chemo)therapy was carried out with a median dose of 45 Gy (range 30–68 Gy).

Results

Median follow-up time for surviving patients from the start of R(C)T was 38 months (range 10–105 months). Relief of symptoms was achieved in 19 of 28 symptomatic patients (68%). The median survival time was 12 months (95% confidence interval (CI) 7–17 months) and the median recurrence-free interval was 8 months (95% CI 4–12 months). The survival rates at 1, 2, and 3 years were 55 ± 7%, 29 ± 6%, and 19 ± 5%, respectively. The recurrence-free survival rates at 1, 2, and 3 years were 44 ± 7%, 22 ± 6%, and 15 ± 5%, respectively. A radiation dose ≥ 45 Gy and conformal RT were associated with a better prognosis.

Conclusion

RT is feasible and effective in the management of recurrent esophageal carcinoma, especially for relief of symptoms. Toxicity is in an acceptable range. The outcome of REC is poor; however, long-term survival of patients with recurrent esophageal carcinoma after radiochemotherpy might be possible, even with a previous history of radiotherapy in the initial treatment. If re-irradiation of esophageal carcinoma is contemplated, three-dimensional conformal techniques and a minimum total dose of 45 Gy are recommended.
Literatur
1.
Zurück zum Zitat Tam PC, Siu KF, Cheung HC et al (1987) Local recurrence after subtotal esophagectomy for squamous cell carcinoma. Ann Surg 205:189–194PubMedCrossRef Tam PC, Siu KF, Cheung HC et al (1987) Local recurrence after subtotal esophagectomy for squamous cell carcinoma. Ann Surg 205:189–194PubMedCrossRef
2.
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317PubMedCrossRef Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317PubMedCrossRef
3.
Zurück zum Zitat Schmidberger H, Hess CF, Becker H et al (2009) Ösophagus. In: Bamberg M, Molls M, Sack H (eds) Radioonkologie (Klinik) 2nd edn. Zuckschwerdt, München, pp 317–344 (in German) Schmidberger H, Hess CF, Becker H et al (2009) Ösophagus. In: Bamberg M, Molls M, Sack H (eds) Radioonkologie (Klinik) 2nd edn. Zuckschwerdt, München, pp 317–344 (in German)
4.
Zurück zum Zitat Yano M, Takachi K, Doki Y et al (2006) Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 19:73–77PubMedCrossRef Yano M, Takachi K, Doki Y et al (2006) Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 19:73–77PubMedCrossRef
5.
Zurück zum Zitat Shioyama Y, Nakamura K, Ohga S et al (2007) Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol 37(12):918–923PubMedCrossRef Shioyama Y, Nakamura K, Ohga S et al (2007) Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol 37(12):918–923PubMedCrossRef
6.
Zurück zum Zitat Nakamura T, Ota M, Narumiya K et al (2008) Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol 15:2451–2457PubMedCrossRef Nakamura T, Ota M, Narumiya K et al (2008) Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol 15:2451–2457PubMedCrossRef
7.
Zurück zum Zitat Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31PubMedCrossRef Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31PubMedCrossRef
8.
Zurück zum Zitat Raoul JL, Le Prise E, Meunier B et al (1995) Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37:174–176PubMedCrossRef Raoul JL, Le Prise E, Meunier B et al (1995) Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37:174–176PubMedCrossRef
9.
Zurück zum Zitat Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedCrossRef Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598PubMedCrossRef
10.
Zurück zum Zitat Fritz P, Schraube P, Oberle J et al (1992) Perkutan-endokavitäre Strahlenbehandlung der Ösophaguskarzinome. Strahlenther Onkol 168:154–161 (in German)PubMed Fritz P, Schraube P, Oberle J et al (1992) Perkutan-endokavitäre Strahlenbehandlung der Ösophaguskarzinome. Strahlenther Onkol 168:154–161 (in German)PubMed
11.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRef Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRef
12.
Zurück zum Zitat Fritz P, Stoll P, Wannenmacher M et al (2003) Primäre Radiochemotherapie inoperabler fortgeschrittener Ösophaguskarzinome. Strahlenther Onkol 179:328–336 (in German)PubMedCrossRef Fritz P, Stoll P, Wannenmacher M et al (2003) Primäre Radiochemotherapie inoperabler fortgeschrittener Ösophaguskarzinome. Strahlenther Onkol 179:328–336 (in German)PubMedCrossRef
13.
Zurück zum Zitat Sykes AJ, Burt PA, Slevin NJ et al (1998) Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 48:15–21PubMedCrossRef Sykes AJ, Burt PA, Slevin NJ et al (1998) Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 48:15–21PubMedCrossRef
14.
Zurück zum Zitat Jingu K, Nemoto K, Matsushita H et al (2006) Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 6:1–9CrossRef Jingu K, Nemoto K, Matsushita H et al (2006) Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 6:1–9CrossRef
15.
Zurück zum Zitat Nishimura Y, Koike R, Nakamatsu K et al (2003) Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative or residual esophageal cancer. Jpn J Clin Oncol 33:341–345PubMedCrossRef Nishimura Y, Koike R, Nakamatsu K et al (2003) Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative or residual esophageal cancer. Jpn J Clin Oncol 33:341–345PubMedCrossRef
16.
Zurück zum Zitat Nemoto K, Ariga H, Kakuto Y et al (2001) Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 61:165–168PubMedCrossRef Nemoto K, Ariga H, Kakuto Y et al (2001) Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 61:165–168PubMedCrossRef
17.
Zurück zum Zitat Koide N, Hiraguri M, Nishio A et al (2001) Ulcer in the gastric tube for esophageal replacement: a comparison of 12 esophageal cancer patients with or without postoperative radiotherapy. J Gastroenterol Hepatol 16:137–141PubMedCrossRef Koide N, Hiraguri M, Nishio A et al (2001) Ulcer in the gastric tube for esophageal replacement: a comparison of 12 esophageal cancer patients with or without postoperative radiotherapy. J Gastroenterol Hepatol 16:137–141PubMedCrossRef
18.
Zurück zum Zitat Zieren HU, Muller JM, Jacobi CA et al (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 19:444–449PubMedCrossRef Zieren HU, Muller JM, Jacobi CA et al (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 19:444–449PubMedCrossRef
19.
Zurück zum Zitat Baxi SH, Burmeister B, Harvey JA et al (2008) Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol 52:583–587PubMedCrossRef Baxi SH, Burmeister B, Harvey JA et al (2008) Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol 52:583–587PubMedCrossRef
20.
Zurück zum Zitat Yamashita H, Nakagawa K, Tago M et al (2005) Salvage radiotherapy for postoperative loco-regional recurrence of esophageal Cancer. Dis Esophagus 18:215–220PubMedCrossRef Yamashita H, Nakagawa K, Tago M et al (2005) Salvage radiotherapy for postoperative loco-regional recurrence of esophageal Cancer. Dis Esophagus 18:215–220PubMedCrossRef
21.
Zurück zum Zitat Nemoto K, Matsushita H, Ogawa Y et al (2003) Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 26:46–49PubMedCrossRef Nemoto K, Matsushita H, Ogawa Y et al (2003) Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 26:46–49PubMedCrossRef
22.
Zurück zum Zitat Maruyama K, Motoyama S, Anbai A et al (2011) Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus 3:166–171CrossRef Maruyama K, Motoyama S, Anbai A et al (2011) Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus 3:166–171CrossRef
23.
Zurück zum Zitat Moureau-Zabotto L, Touboul E, Lerouge D et al (2005) Impact of CT and 18F-Deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63:340–345PubMedCrossRef Moureau-Zabotto L, Touboul E, Lerouge D et al (2005) Impact of CT and 18F-Deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63:340–345PubMedCrossRef
24.
Zurück zum Zitat Lammering G, De Ruysscher D, Baardwijk A van et al (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186:471–481PubMedCrossRef Lammering G, De Ruysscher D, Baardwijk A van et al (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186:471–481PubMedCrossRef
25.
Zurück zum Zitat Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202–3210PubMed Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202–3210PubMed
26.
Zurück zum Zitat Berger B, Belka C, Weinmann M et al (2010) Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma. Strahlenther Onkol 186:255–261PubMedCrossRef Berger B, Belka C, Weinmann M et al (2010) Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma. Strahlenther Onkol 186:255–261PubMedCrossRef
27.
Zurück zum Zitat Zwicker F, Roeder F, Thieke C (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32–38PubMedCrossRef Zwicker F, Roeder F, Thieke C (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32–38PubMedCrossRef
28.
Zurück zum Zitat Wolf M, Zehentmayr F, Niyazi M (2010) Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 186:374–381PubMedCrossRef Wolf M, Zehentmayr F, Niyazi M (2010) Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 186:374–381PubMedCrossRef
29.
Zurück zum Zitat Anonymous (1995) LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 31:1049–1091CrossRef Anonymous (1995) LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 31:1049–1091CrossRef
Metadaten
Titel
Salvage radiotherapy in patients with recurrent esophageal carcinoma
verfasst von
K. Fakhrian
N. Gamisch
T. Schuster
R. Thamm
M. Molls
H. Geinitz
Publikationsdatum
01.02.2012
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-011-0023-x

Weitere Artikel der Ausgabe 2/2012

Strahlentherapie und Onkologie 2/2012 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Adressen, Personalia, Preisausschreibung, Tagungen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.